Floatz logo

P-Cd19Cd20-Allo1

Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Poseida Therapeutics, Inc.Cell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

86 Active assets in the Primary Mediastinal Large B-cell Lymphoma (PMBCL) cohort.

Asset / SponsorPhaseRating
Ifosfamide
David Bond, MD
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB
Inno-206
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB
Inno-206
University of Washington
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB

View all 50 →

Same molecule, other indications

P-Cd19Cd20-Allo1 is also rated in:

diffuse large B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
follicular lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
high grade B-cell lymphomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →